The successful treatment of mania due to acquired immunodeficiency syndrome using ziprasidone: A case series

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 22, Issue 1, 2010, Pages 111-114

  Spiegel, David R ^a   Weller, Amanda L ^a   Pennell, Kirsten ^a   Turner, Krista ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; OLANZAPINE; PENICILLIN G; RISPERIDONE; ZIPRASIDONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FOLLOW UP; GRANDIOSE DELUSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOENCEPHALOPATHY; MANIA; MENTAL HEALTH; NEUROSYPHILIS; PRIORITY JOURNAL; YOUNG MANIA RATING SCALE;

EID: 76749169515     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2010.22.1.111     Document Type: Article

References (17)

1. Dubé B, Benton T, Cruess DG, et al: Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci 2005; 30:237-246
2. Ellen SR, Judd FK, Mijch AM, et al: Secondary mania in patients with HIV infection. Aust N Z J Psychiatry 1999; 33:353-360
3. Ferrando SJ, Nims C: HIV-associated mania treated with electroconvulsive therapy and highly-active antiretroviral therapy. Psychosomatics 2006; 47:170-174
4. Lyketsos GC, Schwartz J, Fishman M, et al: AIDS mania. J Neuropsychiatry Clin Neurosci 1997; 9:277-279
5. Mijch AM, Judd FK, Lyketsos CG, et al: Secondary mania in patients with HIV infection: are antiretrovirals protective? J Neuropsychiatry Clin Neurosci 1999; 11:475-480
6. Lipton SA: Neuronal injury associated with HIV-1 and potential treatment with calcium-channel and NMDA antagonists. Dev Neurosci 1994; 16:145-151
7. Ferrando SJ, Wapenyi K: Psychopharmacological treatment of patients with HIV and AIDS. Psychiatr Q 2002; 73:33-49
8. Mendez MF: Mania in neurological disorders. Curr Psychiatry Rep 2000; 2:440-445
9. Cummings J: Anatomic and behavioral aspects of frontal-subcortical circuits. Ann N Y Acad Sci 1995; 769:1-13
10. Pearlson GD, Wong DF, Tune LE, et al: In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 1995; 52:471-477
11. Honey GD, Suckling J, Zelaya F, et al: Dopaminergic drug effects on physiological connectivity in a human corticostriato-thalamic system. Brain 2003; 126:1767-1781
12. Versiani M: Ziprasidone in bipolar disorder. Expert Opin Pharmacother 2006; 7:1221-1228
13. Meyer JM, Marsh J, Simpson G: Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient. Biol Psychiatry 1998; 44:791-794
14. Falutz J: Therapy insight: body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Pract Endocrinol Metab 2007; 3:651-661
15. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596-601
16. Tandon R: Ziprasidone appears to offer important therapeutic and tolerability advantages over conventional, and some novel, antipsychotics. Br J Clin Pharmacol 2000; 49(suppl):1S-3S
17. Singh A, Golledge H, Catalan J: Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. J Psychosom Res 1997 42:489-493